Diabetes and Its Complications: Strategies to Advance Therapy and Optimize R&D

By Allan B. Haberman, PhD
 

Tables

Table 1.1. Major Social and Economic Factors that Drive the Worldwide Increase in Obesity

Table 3.1 Selected Genetic Factors Implicated in Development of Beta-Cell Dysfunction in Type 2 Diabetes

Table 4.1. Established Classes of Oral Drugs for Treatment of Type 2 Diabetes

Table 5.1 Classes of Antidiabetic Drugs Introduced into the Market since 2005

Table 5.2. Novel Classes of Antidiabetic Drugs Now in Clinical Trials

Table 6.1. Selected Research-Stage Agents and Novel Therapeutic Strategies for Type 2 Diabetes

Table 7.1. Selected Pipeline Drugs for Diabetic Complications

Figures

Figure 1.1. Projected Growth in Worldwide Prevalence of Diabetes, 1985 to 2030

Figure 3.1. Insulin-Signaling Pathway

Figure 5.1. Future Prospects for DPP-IV Inhibitors

Figure 6.1. Involvement in Novel Biomarker Discovery

Figure 6.2. Importance of Novel Biomarkers in Design of Clinical Trials for Antidiabetic Drugs

Figure 6.3. Importance of R&D Collaboration

Figure 6.4. Primary Mode of Collaboration

Figure 6.5. Diabetes Product Areas Represented by Respondents

Figure 6.6. Physiological and Biochemical Pathways Addressed by Pipeline Drugs for Type 2 Diabetes

Figure 7.1. Unified Diabetic Complications Model